Acorda Can't Add $66M To Award In Ampyra Royalty Fight
The Second Circuit on Wednesday refused to alter an arbitral award issued to Acorda Therapeutics to include nearly $66 million beyond the $16.6 million it won in a multiple sclerosis drug...To view the full article, register now.
Already a subscriber? Click here to view full article